AMGN Dazodalibep: Phase 3 Sjögren's Win, No Magnitude

Amgen’s $27.8 billion Horizon Therapeutics acquisition has been an anchor on the stock since it closed in 2023, and dazodalibep is the first asset from that deal to post a clean Phase 3 win. The Phase 3 OASIZ 301 study met its primary endpoint, the change from baseline in ESSDAI score at Week 48, in 621 adults with moderate-to-severe systemic Sjögren’s disease. The stock barely moved, and at $406 Amgen is up less than 1% on the news. That is the correct reaction, and the reason it is correct tells you everything about how to value this catalyst.

First, the science. Dazodalibep is a CD40 ligand fusion protein, meaning it blocks the CD40/CD40L co-stimulation pathway that sits upstream of B-cell and T-cell activation. It came into Amgen’s hands through a chain of deals: Horizon picked it up in its 2021 acquisition of AstraZeneca spinout Viela Bio for about $3 billion, and Amgen then bought Horizon in 2023 for $27.8 billion in a deal built around the thyroid eye disease drug Tepezza. Sjögren’s is a systemic autoimmune disease with no approved disease-modifying therapy, which is the headline that matters. Roughly 0.25% of the population has it, it is nine times more common in women than men, and it is the second most common autoimmune rheumatic disease after rheumatoid arthritis. Over 90% of patients have dry eyes and dry mouth, but the systemic form attacks organs beyond the glands, which is why an ESSDAI-based endpoint, not a dryness measure, is what regulators want to see.

The Phase 2 data already told us the drug works. In a crossover trial published in Nature Medicine, dazodalibep produced a 6.3-point ESSDAI reduction versus 4.1 for placebo at day 169, a 2.2-point placebo-adjusted difference with a p-value of 0.0167. That is a real effect, and it is the number the Phase 3 was designed to confirm. OASIZ 301 met its endpoint with separation as early as Week 4, sustained through Week 48, which is the durability signal you want in a chronic disease. Safety was clean: nasopharyngitis, urinary tract infection, hypertension, and infusion-related reactions were the most common adverse events, all mild to moderate, with no imbalance in thromboembolic events or opportunistic infections. The thromboembolic point is important because first-generation anti-CD40L antibodies were shelved for exactly that toxicity, and dazodalibep has now shown in two trials that it does not carry that baggage. That clean safety record is the technical moat that lets Amgen’s CD40L program go where earlier drugs could not.

Here is where the valuation gets hard, and where the bull case stalls. Amgen did $36.75 billion in revenue in 2025. Even if dazodalibep reaches the $4.5 billion peak sales Jefferies now models, with about $2 billion of that from Sjögren’s specifically, that is a mid-single-digit percentage of Amgen’s top line arriving several years from now. At a $219 billion market cap, a $4.5 billion peak sales asset is a rounding error, not a re-rating event. Compare that to what a Sjögren’s win means for a pure play, and you see the gap. There is no direct public pure play in Sjögren’s, but the contrast with a company like Argenx, which re-rated by tens of billions on a single autoimmune franchise, makes the point: a first-in-class autoimmune drug is worth far more to a focused company than to a mega-cap where it competes for capital with Prolia, Repatha, Tezspire, and a dozen other franchises. This is the large-cap pharma catalyst immateriality pattern in the immunology catalysts ranking in its purest form.

The competitive picture is also more crowded than the “no approved therapy” headline suggests. Novartis’s ianalumab, a dual-mechanism B-cell depleter that also blocks BAFF-R, already won both of its Phase 3 NEPTUNUS trials and has Breakthrough Therapy designation, with a global filing expected. Ianalumab’s effect sizes were thinner than dazodalibep’s Phase 2: a 6.4 versus 5.1 ESSDAI reduction in NEPTUNUS-1 (275 patients) and 6.5 versus 5.5 in NEPTUNUS-2 (504 patients), placebo-adjusted differences of 1.3 and 1.0 points with p-values of 0.0496 and 0.041. Those are razor-thin margins against a high placebo effect, which is the chronic problem in Sjögren’s trials. Dazodalibep’s 2.2-point Phase 2 delta is stronger, which is the bull’s best argument for it being the better drug. But ianalumab is already at the filing stage while dazodalibep still needs OASIZ 303, its second Phase 3, to read out. Amgen is second to market in the best case, and second-to-market in a disease with no established biologic prescribing habit is a slower launch than the headline would imply. The CD40L platform also has readthrough potential into lupus and other autoantibody-driven diseases, and that optionality, not the Sjögren’s launch itself, is what analysts are actually underwriting when they lift peak sales estimates. Lupus is the prize the market actually cares about, because it is where the same upstream co-stimulation biology has already produced a wave of activity, from FcRn blockers like nipocalimab, which just posted a Phase 2 win in lupus, to B-cell depleters. A CD40L program that proves itself in Sjögren’s gives Amgen a credible card to play in a far larger autoimmune hand, and that is the real reason to track dazodalibep beyond the narrow Sjögren’s launch. Industry estimates put the diagnosed Sjögren’s population in the low single-digit millions in the US and Europe, and the systemic, moderate-to-severe segment Amgen is targeting is a fraction of that. Peak sales estimates for the whole disease have historically ranged from roughly $1 billion to $4 billion depending on how aggressively you assume biologics penetrate an under-treated market. The bear case on the commercial side is that Sjögren’s has gone decades without an approved therapy partly because the prescribing habit never formed: patients are scattered across rheumatology, ophthalmology, and primary care, and no one specialty owns the diagnosis. That fragmentation is a real launch friction that a pure-play company would have to fight for, and it is precisely the kind of commercial problem a mega-cap like Amgen can afford to under-invest in, which is another reason the stock will not trade on this news.

The honest risk list: first, Amgen disclosed no ESSDAI magnitude for OASIZ 301, only that it was “statistically significant and clinically meaningful,” so the Phase 2-to-Phase 3 effect size comparison against ianalumab is not yet possible on a like-for-like basis. Second, the FDA will likely want two positive Phase 3 trials before approval, per William Blair’s read, so OASIZ 303 is a binary event still ahead. Third, ianalumab’s Breakthrough Therapy designation means it could reach the market first and set the reimbursement bar in a disease with no existing price anchor. Fourth, Amgen’s Horizon bet is still under water as a whole: Tepezza faces competitive pressure, and one positive Phase 3 in Sjögren’s does not rescue the $27.8 billion thesis on its own.

The verdict: this is a real scientific win that changes almost nothing about the Amgen investment case. The CD40L mechanism is validated, the Horizon pipeline has a pulse, and Amgen has a credible first-in-class shot in a wholly unserved autoimmune indication. But at $219 billion market cap and $36.75 billion in revenue, a $4.5 billion peak sales asset arriving post-2028 is a Hold, not a Buy. If you want Sjögren’s exposure, Amgen is the wrong vehicle; the right trade is to watch whether OASIZ 303 confirms with a magnitude that beats ianalumab’s thin 1.0 to 1.3-point deltas, because that is the only thing that would make dazodalibep more than a footnote to the Horizon deal. For the stock itself, the science is real and the stock impact is zero, and the Amgen thesis still rides on the Tezspire franchise rather than on a single orphan autoimmune indication. Track OASIZ 301 on ClinicalTrials.gov if you want to see the full magnitude when Amgen presents it, which is the data point that will actually matter.